company profile
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia’s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects.
vista's key points
- Proprietary Diffusphere™ extended-release technology platform
- Global multi-billion dollar market for lead candidate in osteoarthritis
- Lead product candidate for treatment of OA symptoms is widely used corticosteroid with well-established systemic safety record & Additional non-clinical candidates in post-surgical pain, anti-infective and veterinary indications, and potentially in oncology.
- Compelling research results for lead candidate
- Lower risk approval pathway using U.S. 505(b)(2) application Open IND with the FDA for Phase 2 study Use of proceeds support completion of Phase 2 study Manufacturing at initial commercial launch scale
- Extensive medical, life science and public company experience
VISTA'S PROGRESS REPORT
Coming Soon
vista's key points
- Proprietary Diffusphere™ extended-release technology platform
- Global multi-billion dollar market for lead candidate in osteoarthritis
- Lead product candidate for treatment of OA symptoms is widely used corticosteroid with well-established systemic safety record & Additional non-clinical candidates in post-surgical pain, anti-infective and veterinary indications, and potentially in oncology.
- Compelling research results for lead candidate
- Lower risk approval pathway using U.S. 505(b)(2) application Open IND with the FDA for Phase 2 study Use of proceeds support completion of Phase 2 study Manufacturing at initial commercial launch scale
- Extensive medical, life science and public company experience
exclusive content
Vista Partners creates exclusive content based on the ongoing research of companies included in the VP Watchlist.
vp watchlist
The VP Watchlist contains current coverage companies that deserve consideration for short term and long term portfolio additions.
recent news
-
Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release...
20 November 2024 | 12:00 pm
-
Eupraxia Pharmaceuticals to Present at American College...
14 November 2024 | 10:00 pm
-
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to...
13 November 2024 | 10:00 pm
Interviews
Coming Soon
Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities.
Get Free Email Updatesvideos
Coming Soon